Stockscreener 앱 받기
10.75
0.84%
0.09
시간 외 거래:
10.75
전일 마감가:
$10.66
열려 있는:
$10.68
하루 거래량:
521.51K
Relative Volume:
1.07
시가총액:
$654.18M
수익:
$5.03M
순이익/손실:
$-185.41M
주가수익비율:
-3.479
EPS:
-3.09
순현금흐름:
$-139.79M
1주 성능:
-1.56%
1개월 성능:
-18.38%
6개월 성능:
-24.88%
1년 성능:
-40.01%
1일 변동 폭
$10.54
$11.06
1주일 범위
$10.54
$11.40
52주 변동 폭
$10.22
$18.46
Pliant Therapeutics Inc Stock (PLRX) Company Profile
명칭
Pliant Therapeutics Inc
전화
650-481-6770
주소
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
PLRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
10.75 | 654.18M | 5.03M | -185.41M | -139.79M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-05-18 | 개시 | Canaccord Genuity | Buy |
| 2023-04-13 | 개시 | Robert W. Baird | Outperform |
| 2022-12-14 | 개시 | Stifel | Buy |
| 2022-12-07 | 개시 | JP Morgan | Overweight |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2022-07-20 | 개시 | SVB Leerink | Outperform |
| 2022-05-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-12-10 | 개시 | Oppenheimer | Outperform |
| 2021-11-24 | 개시 | RBC Capital Mkts | Outperform |
| 2021-11-03 | 개시 | H.C. Wainwright | Buy |
| 2021-04-20 | 개시 | BTIG Research | Buy |
| 2021-04-05 | 개시 | Citigroup | Buy |
| 2020-06-29 | 개시 | Citigroup | Buy |
| 2020-06-29 | 개시 | Cowen | Outperform |
| 2020-06-29 | 개시 | Needham | Buy |
| 2020-06-29 | 개시 | Piper Sandler | Overweight |
모두보기
Pliant Therapeutics Inc 주식(PLRX)의 최신 뉴스
(PLRX) Proactive Strategies - Stock Traders Daily
PLRX (Pliant Therapeutics) Momentum Rank : 7 (As of Jan. 24, 2025) - GuruFocus.com
Pliant Therapeutics' chief human resource officer sells $41,892 in stock By Investing.com - Investing.com South Africa
Insider Selling: Pliant Therapeutics, Inc. (NASDAQ:PLRX) General Counsel Sells 10,230 Shares of Stock - MarketBeat
Bernard Coulie Sells 52,419 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) Stock - MarketBeat
Pliant Therapeutics, Inc. (NASDAQ:PLRX) General Counsel Mike Ouimette Sells 13,270 Shares - MarketBeat
Pliant Therapeutics' chief human resource officer sells $41,892 in stock - MSN
Pliant Therapeutics general counsel Mike Ouimette sells $261,100 in stock - Investing.com India
Pliant Therapeutics chief business officer Hull sells $178,500 in stock By Investing.com - Investing.com Australia
Brokers Issue Forecasts for PLRX FY2025 Earnings - Defense World
Pliant Therapeutics CEO Bernard Coulie sells stock for $587,150 - MSN
Pliant Therapeutics CFO sells $225,679 in stock By Investing.com - Investing.com Canada
Pliant Therapeutics CEO Bernard Coulie sells stock for $587,150 By Investing.com - Investing.com South Africa
Pliant Therapeutics CFO sells $225,679 in stock - MSN
Pliant Therapeutics chief business officer Hull sells $178,500 in stock - Investing.com India
Pliant Therapeutics' chief medical officer sells $206,973 in stock By Investing.com - Investing.com South Africa
Pliant Therapeutics' chief medical officer sells $206,973 in stock - Investing.com
Pliant Therapeutics general counsel Mike Ouimette sells $261,100 in stock By Investing.com - Investing.com UK
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Pliant Therapeutics Grants 275,000 Stock Options to New Chief Technical Officer - StockTitan
Pliant Therapeutics appoints new Chief Technical Officer By Investing.com - Investing.com Australia
Pliant Therapeutics appoints new Chief Technical Officer - Investing.com
Pliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical Officer - GlobeNewswire
Pliant Therapeutics Strengthens Leadership Team with Veteran CTO Appointment for Commercial Push - StockTitan
Cantor Fitzgerald Forecasts PLRX FY2025 Earnings - MarketBeat
Pliant Therapeutics (NASDAQ:PLRX) versus EOM Pharmaceuticals (OTCMKTS:IMUC) Head to Head Analysis - Defense World
PLRX (Pliant Therapeutics) 3-Year EPS without NRI Growth Ra - GuruFocus.com
PLRX (Pliant Therapeutics) Forward Rate of Return (Yacktman) % : 0.00% (As of Sep. 2024) - GuruFocus.com
Pliant Therapeutics (NASDAQ:PLRX) Shares Down 5.2%Here's Why - MarketBeat
Learn to Evaluate (PLRX) using the Charts - Stock Traders Daily
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Pliant Therapeutics (NASDAQ:PLRX) Stock Price Up 11%Still a Buy? - MarketBeat
Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Pliant Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Pliant Therapeutics (NASDAQ:PLRX) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Stock Position Boosted by Geode Capital Management LLC - Defense World
Pliant Therapeutics (NASDAQ:PLRX) Trading Down 4.9%Time to Sell? - MarketBeat
Contrasting Pliant Therapeutics (NASDAQ:PLRX) & Bionomics (NASDAQ:BNOX) - Defense World
When (PLRX) Moves Investors should Listen - Stock Traders Daily
State Street Corp Raises Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Rating of “Buy” from Brokerages - Defense World
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives $40.50 Consensus Price Target from Analysts - MarketBeat
Pliant Therapeutics Inc (PLRX): A New Perspective - Stocks Register
Pliant Therapeutics (NASDAQ:PLRX) Stock Price Up 3.6%Should You Buy? - MarketBeat
The Manufacturers Life Insurance Company Cuts Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Purchased by Polar Asset Management Partners Inc. - MarketBeat
Pliant Therapeutics Inc (PLRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.95%
2.39%
자본화:
|
볼륨(24시간):